Would you consider "adjuvant" pembrolizumab for a patient with muscle invasive bladder cancer who is cisplatin ineligible and found at surgery to have T4aN2M0 disease?   

This good question will be answered in the ongoing AMBASSADOR trial led by @Andrea B. Apolo at NCI (pembro vs observation phase 3 adjuvant trial). There is also another adjuvant IO trial: Checkmate-274 trial (nivolumab vs placebo), while IMvigor010 did not meet primary endpoint of DFS benefit w...